Neurogene Inc.
neurogene.comWhat Do They Do?
Develops genetic medicines for rare neurological diseases, including a gene therapy for Rett syndrome, for people affected by those conditions.
10-K for FY2025, filed Mar 24, 2026Despite recent scientific advances in genetics, most neurological diseases, particularly those with devastating consequences to patients…View ↗
Our first clinical-stage program, NGN-401 in development for the treatment of Rett syndrome, utilizes the EXACT technology and…View ↗
Our pipeline is focused on the development of genetic medicines for severe neurological diseases. Our most advanced program, NGN‑401, is in…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 11, 2026
−$34.5MView ↗
- ▲ +57% (Loss)
- vs −$22M in Q2 FY2025
From protein design to genetic medicines
The older report described de novo protein design and cytokine mimetics for cancer and inflammatory conditions; the latest report describes genetic medicines for rare neurological diseases, including gene therapy for Rett syndrome.
10-K for FY2022, filed Mar 20, 2023 10-K for FY2025, filed Mar 24, 2026
Who Do They Compete With?
Competes with Taysha Gene Therapies and Acadia
10-K for FY2025, filed Mar 24, 2026While no disease-modifying therapies are currently available on the market for the treatment of Rett syndrome, we are aware of several…View ↗
Loading...
